Euroscreen raises $17.8 mln
Euroscreen said Friday it raised 16 million euros (US$17.8 million) in a series B funding round. SFPI-FPIM and Fund+ co-led the round. Existing shareholders including Vesalius Biocapital II Partners, SRIW SA, BNP Paribas Fortis Private Equity, as well as new comer as Capricorn Health-Tech Fund NV also participated. Euroscreen, a drug development company, is backed by Vesalius Biocapital, SFPI-FPIM, SRIW, Fund+ and BNP Paribas Fortis Private Equity.
2 October 2015•4 mins read
